Jeff Jonas, Kenai Therapeutics chairman

'Sweet spot' of CNS cell ther­a­py: Ke­nai emerges with $82M for Parkin­son's study

One of the first drugs that Jeff Jonas filed for ap­proval was a Parkin­son’s dis­ease treat­ment. Now, a lit­tle over a quar­ter-cen­tu­ry lat­er, af­ter ex­ec­u­tive roles at Shire and Sage Ther­a­peu­tics, he’s chair­ing a young start­up with $82 mil­lion to test whether an off-the-shelf cell ther­a­py can treat the CNS dis­or­der.

Ke­nai Ther­a­peu­tics emerged Thurs­day with the Se­ries A co-led by Alas­ka Per­ma­nent Fund Cor­po­ra­tion, The Col­umn Group and Cure Ven­tures, where Jonas is a part­ner.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.